Cellares

About Cellares

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) focused on accelerating access to life-saving cell therapies. Their mission is to overcome the limitations of conventional Contract Development and Manufacturing Organizations (CDMOs) by providing unparalleled scalability, cost savings, quality, and flexibility in cell therapy manufacturing.

Products & Services

Cell Shuttle™:A modular, cGMP platform for industrial-scale cell therapy manufacturing.

Consumable Cartridge:True end-to-end automation in a closed and automated single-use cartridge.

Cell Q™:Automated, high-throughput QC platform for cell therapies.

Software:Flexible and fully integrated cell therapy manufacturing software suite.

IDMO Services:Integrated development and manufacturing services for cell therapies with a focus on scalability, cost savings, and quality.

Cell Shuttle

Cell Q

IDMO Services

Specialties

Cell Therapy Manufacturing Automated Manufacturing Technologies Integrated Development and Manufacturing Organization (IDMO) Scalability in Cell Therapies Quality Control Platforms Automated cell therapy manufacturing Process translation and automation Analytical method automation Global regulatory consultation Smart Factory operations

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 327000000 MR: - FA: 327000000 FAN: 327000000	D: 2026-06-15 FD: 2026-06-15	13 investors
2	RT: Series D T: - FT: Series D	A: 277000000 MR: - FA: $277 million FAN: 277000000	D: 2026-06-09 FD: 2026-06-09	12 investors
3	RT: Series D T: - FT: Series D	A: 257000000 MR: - FA: $257 million FAN: 257000000	D: 2026-01-28 FD: 2026-01-28	11 investors
4	RT: Series C T: - FT: Series C	A: 255000000 MR: - FA: $255 million FAN: 255000000	D: 2024-01-25 FD: 2024-01-25	-
5	RT: Series C T: - FT: Series C	A: 255000000 MR: - FA: $255 million FAN: 255000000	D: 2023-08-23 FD: 2023-08-23	7 investors

Series D Latest

2026-06-15

$327.0M

13 investors (Pro only)

Series D 2026-06-09

$277.0M

Series D 2026-01-28

$257.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

Fabian Gerlinghaus

Co-Founder & CEO, Cellares

O

Omar Kurdi

Co-Founder & President, Cellares

J

Joe Fath

Partner and Head of Growth, Eclipse

V

Victor Tong

Managing Director, Decheng Capital

B

Byron Knight

President & COO, Koch Disruptive Technologies

C

Carl June

Professor in Immunotherapy, University of Pennsylvania

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

Cellares Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised